About oruka therapeutics inc - ORKA
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
ORKA At a Glance
Oruka Therapeutics, Inc.
855 Oak Grove Avenue
Menlo Park, California 94025
| Phone | 1-650-606-7910 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -83,724,000.00 | |
| Sector | Health Technology | Employees | 28 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ORKA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.914 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.524 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.021 |
ORKA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,990,142.857 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ORKA Liquidity
| Current Ratio | 28.894 |
| Quick Ratio | 28.894 |
| Cash Ratio | 28.801 |
ORKA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -38.593 |
| Return on Equity | -39.941 |
| Return on Total Capital | -21.849 |
| Return on Invested Capital | -39.85 |
ORKA Capital Structure
| Total Debt to Total Equity | 0.253 |
| Total Debt to Total Capital | 0.253 |
| Total Debt to Total Assets | 0.244 |
| Long-Term Debt to Equity | 0.199 |
| Long-Term Debt to Total Capital | 0.197 |